Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, December 31, 2021.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$50.64M
Return on Equity (ROE)
-90.44%
TTM Avg
-163.19%
3Y Avg
-112.62%
5Y Avg
-86.58%
Market Cap
$49.47M
Return on Equity (ROE)
-23.70%
TTM Avg
-170.56%
3Y Avg
-190.10%
5Y Avg
-146.13%
Market Cap
$50.86M
Return on Equity (ROE)
-36114.03%
TTM Avg
-31.09%
3Y Avg
-15.54%
5Y Avg
-12.44%
Market Cap
$51.33M
Return on Equity (ROE)
-708.48%
TTM Avg
156.13%
3Y Avg
510.26%
5Y Avg
342.91%
Market Cap
$49.07M
Return on Equity (ROE)
N/A
TTM Avg
296.81%
3Y Avg
-175.08%
5Y Avg
-1071.79%
Market Cap
$51.78M
Return on Equity (ROE)
N/A
TTM Avg
-382.07%
3Y Avg
-282.25%
5Y Avg
-171.00%
Market Cap
$51.85M
Return on Equity (ROE)
N/A
TTM Avg
31.64%
3Y Avg
119.26%
5Y Avg
-26.51%
Market Cap
$52.31M
Return on Equity (ROE)
-278.89%
TTM Avg
-162.92%
3Y Avg
25.71%
5Y Avg
0.37%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| biote Corp. (BTMD) | $50.28M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $50.64M | -90.44% | -163.19% | -112.62% | -86.58% |
| Microbot Medical Inc. (MBOT)vs › | $49.47M | -23.70% | -170.56% | -190.10% | -146.13% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $50.86M | -36114.03% | -31.09% | -15.54% | -12.44% |
| Envoy Medical, Inc. (COCH)vs › | $51.33M | -708.48% | 156.13% | 510.26% | 342.91% |
| Clene Inc. (CLNN)vs › | $49.07M | N/A | 296.81% | -175.08% | -1071.79% |
| Apollomics, Inc. (APLM)vs › | $51.78M | N/A | -382.07% | -282.25% | -171.00% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.85M | N/A | 31.64% | 119.26% | -26.51% |
| eXoZymes, Inc. (EXOZ)vs › | $52.31M | -278.89% | -162.92% | 25.71% | 0.37% |
| Celularity Inc. (CELU)vs › | $48.05M | N/A | -206.96% | -221.50% | -349.91% |
ROE
N/A
ROA
5.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2021-12-31 | 790.76% |
